FABRIC RINSE COMPOSITION CONTAINING A CATIONIC UV ABSORBER

Details for Australian Patent Application No. 2002240950 (hide)

Owner CIBA SPECIALTY CHEMICALS HOLDING INC.

Inventors HOCHBERG, Robert; ROHWER, Hauke; EHLIS, Thomas

Pub. Number AU-A-2002240950

PCT Pub. Number WO2002/088455

Priority 01810311.9 27.03.01 EP

Filing date 19 March 2002

Wipo publication date 11 November 2002

International Classifications

D06M 013/358 Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compounds

C08K 005/3492 Use of organic ingredients

D06M 013/46 Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compounds

C11D 003/00 Other compounding ingredients of detergent compositions covered in group

C11D 003/28 Other compounding ingredients of detergent compositions covered in group

C11D 003/42 Other compounding ingredients of detergent compositions covered in group

Event Publications

17 April 2003 Application Open to Public Inspection

  Published as AU-A-2002240950

13 July 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002240951-COMPOSITION OF MATTER FOR CAT LITTER

2002240949-PHARMACEUTICAL COMBINED PREPARATIONS CONTAINING AROMATASE INHIBITORS AND SUBSTANCES HAVING AN ESTROGEN EFFECT IN ADDITION TO THE USE THEREOF FOR PRODUCING A MEDICAMENT FOR ESTROGENREPLACEMENT-THERAPY